Race On: China Starts Coronavirus Vaccine Trial, Vows Fast Development
The Race For Covid-19 Vaccines Is Hotting Up
Leveraging on its Ebola vaccine success, Tianjin-based CanSino is testing its vaccine on humans in Wuhan and hopes to get China’s first COVID-19 vaccine on the market soon.
You may also be interested in...
Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.
Ke Wu, CEO of Wuhan-based BravoVax, tells Scrip in an exclusive interview why front-runner vaccines for coronavirus that enter clinical studies may not necessarily be successful, and why small innovative Chinese firms may be best positioned to seize opportunities as the government rallies both internal and external support for the development effort.
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.